FRIDAY JANUARY 18

08.00-08.30 Registration
08.30-09.00 Welcome and introduction
09.00-09.20 Inhibitor management – an era of new options (JA)
09.20-10.00 Immunology – mechanisms and value of tolerance (SLD)
10.00-10.30 Break
10.30-11.15 ITI therapy in severe hemophilia A over the lifespan (CEE)
11.15-12.00 Interactive case discussion – faculty cases to set the scene as well as how to motivate the patient for the ITI procedure (CEE/CH)
12.00-13.00 Lunch
13.00-13.30 Emerging therapies in inhibitor management – what is currently known/unknown? (CH)
13.30-14.30 Interactive case discussion – participants’ cases
14.30-15.00 Break
15.00-15.30 ITI therapy in non-severe hemophilia A (PAH)
15.30-17.00 Interactive case discussion – participants’ cases
18.30-19.30 Evening Symposium (Octapharma)
19.30 - Dinner

SATURDAY JANUARY 19

08.30-09.00 ITI therapy in hemophilia B (JA)
09.00-09.30 Laboratory aspects on inhibitor monitoring (JA/PAH)
09.30-10.00 Break
10.00-11.30 Interactive case discussion – participants’ cases
11.30-12.00 Examination
12.00-12.15 Evaluation and concluding remarks
12.15 - Lunch and departures

FACULTY

Jan Astermark, Malmö, Sweden (JA)
Pål André Holme, Oslo, Norway (PAH)
Carmen Escuriola Ettinghausen, Mörfelden-Walldorf, Germany (CEE)
Cédric Hermans, Brussels, Belgium (CH)
Sébastien Lacroix-Desmazes, Paris, France (SLD)